ArticleJournal of hematology & oncology2013

Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.

Lieke H van der Helm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.